Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

77 results about "Chemotherapy resistant" patented technology

Chemotherapy drug resistance can be intrinsic or acquired: Intrinsic resistance means a cancer cell is resistant from the start. If chemotherapy kills all the nonresistant cells in a tumor, the resistant cells will survive and reproduce. Then the tumor will grow back fully resistant.

Sulfatase-driven polypeptide condensate with chemotherapy sensitization effect and preparation method of sulfatase-driven polypeptide condensate

The invention discloses a sulfatase-driven polypeptide condensate with a chemotherapy sensitization effect and a preparation method thereof, and belongs to the field of biological medicines. According to the principle that sulfatase can catalyze hydrolysis of sulfate bonds, main polypeptide YSO4F responded by sulfatase enzyme is designed and synthesized; and the enzyme response aggregate m-YSO4F-LSG is blended with a protein G3BP2 ligand FGDF-YSO4F to prepare the enzyme response aggregate m-YSO4F-LSG with a sorafenib chemosensitization effect. Tumor cells can generate stress particles with a chemotherapy drug resistance effect under the stimulation of a chemotherapy drug sorafenib, the treatment effect of the sorafenib is weakened, and the protein G3BP2 is one of core proteins of the stress particles. After the m-YSO4F-LSG enters tumor cells, sulfate groups are hydrolyzed under the catalytic action of sulfatase overexpressed in tumor cell lysosomes, so that phase separation liquid drops d-YF-LSG with high affinity to protein G3BP2 are formed in the cells in situ, the phase separation liquid drops d-YF-LSG act with the protein G3BP2 and are fused with stress particles, chemotherapy drug resistance generated by the stress particles is inhibited, and the chemotherapy effect is improved. The treatment effect is improved.
Owner:NANKAI UNIV

Application of fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma

The invention discloses an application of a fatty acid oxidation inhibitor in improving cis-platinum resistance of esophageal squamous carcinoma, and particularly relates to the technical field of biology. The invention discloses application of a fatty acid oxidation inhibitor in preparation of a product for improving cisplatin resistance of esophageal squamous carcinoma. The fatty acid oxidation inhibitor is etomox. The invention discloses a very good effect of the fatty acid beta oxidation inhibitor Etomoxir on weakening the cisplatin resistance of esophageal squamous carcinoma cells induced by M2 type macrophage-derived GDF15 for the first time. According to the invention, the fatty acid beta oxidation inhibitor Etomoxir is combined with cis-platinum to be applied to the treatment process of esophageal cancer, so that the esophageal cancer chemotherapy drug resistance process mediated by tumor-associated macrophages is effectively weakened.
Owner:SHIHEZI UNIVERSITY

Ferric gambogic acid adriamycin nano-particles, preparation method and application

PendingCN119679730AOrganic active ingredientsPowder deliveryAdriamycin HydrochlorideGambogic acid
The invention relates to the technical field of nano medicine, in particular to iron gambogic acid adriamycin nano particles, a preparation method and application. Gambogic acid, doxorubicin hydrochloride and an iron-containing compound are matched, carbonyl oxygen and hydroxyl in the gambogic acid and Fe < 3 + > form coordinate bonds, carbonyl and amino in the doxorubicin hydrochloride and a conjugated system in a benzene ring are combined with Fe < 3 + > through covalent bonds and pi-pi accumulation, a core-shell structure is formed, and the iron gambogic acid doxorubicin nano-particles are obtained. The particle size of the iron gambogic acid adriamycin nano-particles ranges from 2 nm to 10 nm. The iron gambogic acid adriamycin nano-particles have excellent multi-enzyme activity, autophagy amplification is effectively achieved, traditional chemotherapy drug resistance caused by autophagy is overcome, and the glioma chemotherapy effect is improved.
Owner:THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV

Liposome drug delivery system for targeted therapy of brain glioma and application thereof

The invention discloses a lipidosome drug delivery system for targeted therapy of brain glioma and application thereof. The lipidosome drug delivery system is a lipidosome mixture prepared from a basic component, a functional component and an external water-phase buffer solution. After intravenous injection, the liposome is efficiently combined with complement protein C3 and immune globulin M in plasma to synergistically activate a complement system, actively attracts and activates neutrophils to uptake, and crosses a blood brain barrier in a mode of'building a defecation vehicle 'by utilizing the inflammatory taxis of the neutrophils. Neutrophile granulocytes are stimulated by inflammatory factors in a microenvironment after reaching a tumor brain area to form extracellular trap release lipidosome. The lipidosome realizes specific targeting through folate receptors over-expressed on the surfaces of glioma cells. The liposome shows excellent cross-blood-brain-barrier drug delivery efficiency and brain glioma curative effect in vivo, can be effectively combined with surgery, radiotherapy and the like, and provides a solution for the main problems of radiotherapy resistance, chemotherapy drug resistance and the like in clinic.
Owner:TIANJIN MEDICAL UNIV

N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
Owner:MODERN BIOSCI LTD

Method for preparing nk cell-derived nanovesicles and uses thereof

The application provides a preparation method of NK cell-derived nanovesicles and application thereof. Specifically, the application provides NK cell-derived nanovesicles (NK-NVs) which are similar to the characteristics and functions of NK cell-derived extracellular vesicles by an extrusion method / stress gradient membrane remodeling technology, and also provides a drug composition, a drug delivery system and corresponding use of the NK-NVs as a delivery carrier for delivering an antitumor drug. The preparation method of the application can mass-produce NK-NVs and kill various types of tumor cells. The NK-NVs have multiple advantages in drug delivery, so that they are expected to be a new choice for tumor immunotherapy, especially for tumor cells with drug resistance, and can significantly improve the sensitivity to chemotherapeutic drugs, and have a wide application prospect.
Owner:GUIZHOU XINGBOYUAN BIOMEDICAL TECHNOLOGY CO LTD

Human bladder cancer cell line ZSZB1 and application thereof

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.
Owner:LANZHOU UNIV

A reduction-responsive nanodelivery system and use thereof in the preparation of a medicament for treating drug-resistant tumors

ActiveCN117304424BHeterograftsTumor targeting
The application provides a reduction-responsive nano delivery system and application thereof in preparation of a drug for treating drug-resistant tumors, and belongs to the pharmaceutical field. The application constructs a reduction-responsive branched copolymer functionalized by pegylation and deoxycholic acid (DA) (referred to as: pegylated branched poly(HPMA-DA)), which can effectively encapsulate small molecule drugs to form a nano delivery system. Experiments prove that the nano delivery system can be taken up by tumor cells, has good tumor targeting, and exhibits excellent anti-tumor effect in tumor xenografts (CDX) derived from non-small cell lung cancer (NSCLC) chemoresistant cell lines and patient-derived xenograft mouse models (PDX). The pegylated branched poly(HPMA-DA) provided by the application has wide application prospect in preparation of a drug carrier, and the nano delivery system provided by the application has wide application prospect in preparation of a drug for treating cancer.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Carboxymethyl chitosan-based glycolysis regulation nano drug delivery system modified by nucleolin aptamer as well as preparation method and application of carboxymethyl chitosan-based glycolysis regulation nano drug delivery system

The invention discloses a nucleolin aptamer modified carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system as well as a preparation method and application thereof, and relates to the field of tumor treatment. The nucleolin aptamer AS1411 is coupled with glycolysis regulation nano-particles through covalent bonds, and the carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system comprises a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system and a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, the glycolysis regulation nano-particles take carboxymethyl chitosan as a carrier skeleton, the carrier skeleton is loaded with a lonidamine derivative through grafting modification, and the nano drug delivery system can synchronously entrap paclitaxel. According to the invention, a synergistic treatment system integrating active targeting, metabolic regulation and chemotherapy is constructed, and by virtue of a multi-mechanism synergistic effect, an antitumor drug for inhibiting tumor cell activity, glycolysis or tumor metabolism reprogramming is prepared; the huge potentials of overcoming the drug resistance bottleneck of traditional chemotherapy, enhancing the curative effect and reducing the toxic and side effects are shown.
Owner:JINAN MATERNITY & CHILDREN HEALTH HOSPITAL +1

Human NBS1 protein antigen lactylated at lysine 388, antibody, preparation method therefor, and use thereof

Provided are a human NBS1 protein antigen lactylated at lysine 388, an antibody, a preparation method therefor, and a use thereof, relating to the technical field of biomedicine. A human NBS1 protein antigen peptide lactylated at lysine 388 is provided, and is used to prepare an antibody targeting lactylation at lysine 388 of human NBS1 protein. The antibody targeting lactylation at lysine 388 of human NBS1 protein can detect expression differences among normal cells, tumor cells, and drug-treated tumor cells, thereby helping to study the role of lactylation modification of human NBS1 protein in the occurrence and development of tumor diseases, and providing potential therapeutic targets for clinical diagnosis or treatment of tumor diseases. The antibody targeting lactylation at lysine 388 of human NBS1 protein can be used to detect the lactylation level of human NBS1 protein, and to investigate its relationship with tumor diagnosis and resistance to radiotherapy and chemotherapy, thereby offering broad clinical application prospects in disease diagnosis, treatment, and prognosis evaluation.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

Lactylated NBS1 protein and uses thereof

A lactylated NBS1 protein and uses thereof. A lactylation site is lysine 388 of an NBS1 protein. Lactylation at the K388 site of the NBS1 protein activates a DNA repair pathway, and enables various uses including promoting drug resistance of tumor cells in radiotherapy and chemotherapy and enhancing DNA homologous recombination repair. By means of targeted inhibition of the lactylated NBS1 protein, drug resistance of tumors in radiotherapy or chemotherapy can be reversed, providing a potential target for reversing drug resistance of tumors in radiotherapy or chemotherapy.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

Role of uck1 in promoting treatment sensitization of colorectal cancer

PendingCN122440821ATherapy resistantEfficacy
The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1

tRF5-22-sectca-1, tRF5-22-sectca-1 detection reagents, kits and uses thereof

PendingCN122357548AOncologyChemo therapy
This invention belongs to the field of molecular biology technology, specifically involving tRF5-22-SeCTCA-1, tRF5-22-SeCTCA-1 detection reagents, kits, and their applications. This invention discovers and verifies that tRF5-22-SeCTCA-1 plays a key regulatory role in the process of 5-fluorouracil (5-FU) chemotherapy resistance in colorectal cancer, filling a gap in the research of tRNA-derived fragments (tRFs) in colorectal cancer chemotherapy resistance. It is the first tRF molecule reported to be associated with 5-FU chemotherapy resistance in colorectal cancer, providing a novel molecular target and research direction for predicting chemotherapy resistance in colorectal cancer. This invention also provides a therapeutic strategy targeting tRF5-22-SeCTCA-1 and establishes α-ketoglutarate as an independent reversal agent, providing multi-dimensional technical solutions for the precision diagnosis and treatment of colorectal cancer and the reversal of chemotherapy resistance.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Preparation method and application of tumor microparticles encapsulating metabolic inhibitors

A preparation method of a tumor microparticle encapsulating a metabolic inhibitor includes following steps. A tumor cell is cultivated, and a statin drug is added to a culture medium after the tumor cell grows stably. Then, the tumor cell is irradiated with an ultraviolet, and then the tumor cell is incubated in a cell incubator for 22˜26 hours. After the incubation, cell supernatant is collected and the tumor microparticle encapsulating the metabolic inhibitor is obtained through a gradient centrifugation. The preparation method uses tumor cell-derived microparticles as drug delivery platforms, with a simple preparation process that preserves functions such as biosafety, biocompatibility, targeting, and intercellular communication. The preparation method discovers new uses of a statin drug, which can inhibit tumor growths with the statin drug, regulate tumors metabolism and improve a tumor microenvironment, and have a potential to enhance a chemotherapy efficacy and delay a chemotherapy resistance.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Inhibiting cancer chemoresistance and metastasis by targeting doublecortin-like kinase 1 (DCLK1)

A method of treating a Doublecortin-like kinase 1 (DCLKl)-expressing cancer and inhibiting tumor metatastasis in a subject in need of such treatment by (1) providing a self-assembled micelle interfering ribonucleic acid (SAMiRNA) nanoparticle comprising a therapeutically effective amount of an RNA oligonucleotide having inhibitory activity against the expression or biological activity of DCLK1, (2) providing a therapeutically effective amount of a platinum-based anticancer drug, and (3) administering to the subject a combination treatment comprising the SAMiRNA nanoparticle and the platinum-based anticancer drug. The SAMiRNA nanoparticle and the platinum-based anticancer drug may be administered together or separately.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA

1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds (collectively referred to herein as CHMSA compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, hidradenitis suppurativa, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
Owner:ISTESSO THERAPEUTICS LTD

Compositions and methods for treating chemotherapy resistant cancer

The present invention features methods for increasing sensitivity and / or reversing resistance to chemotherapy, methods for treating or preventing a cancer in a subject, methods for treating clonal hematopoiesis of indeterminate potential in a subject, and methods of identifying resistance or sensitivity to chemotherapy in a subject. In some embodiments, the methods contain the step of administering an agent that inhibits the expression or activity of a Protein phosphatase 1D (PPM1D) polypeptide or polynucleotide. The present invention also features compositions for increasing sensitivity and / or reversing resistance to chemotherapy.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Application of CCT6A inhibitor in preparation of medicine for treating colorectal cancer

The invention belongs to the technical field of biological medicines, and discloses application of a CCT6A inhibitor in preparation of a medicine for treating colorectal cancer. CCT6A is determined to be a key cancer promoting gene of colorectal cancer for the first time, the CCT6A is remarkably and highly expressed in colorectal cancer tissues and cell lines, and high expression indicates poor prognosis of patients, so that a brand-new specific target is provided for targeted therapy of colorectal cancer. The invention discloses the cancer promoting effect of the compound in colorectal cancer and the association with 5FU drug resistance for the first time, enriches the development of colorectal cancer and the molecular mechanism research of chemotherapy drug resistance, and provides a new theoretical basis and research direction for the fundamental research in the field. Experiments prove that the inhibitor can significantly reduce the mRNA level of CCT6A in colorectal cancer cells so as to strongly inhibit tumor cell proliferation and increase the sensitivity of the colorectal cancer cells to 5-FU, and a novel therapeutic drug with high specificity and high curative effect is provided for treatment of colorectal cancer.
Owner:GUANGZHOU CUNZHONG TECHNOLOGY SERVICE CO LTD

Method for capturing, identifying and culturing sarcoma circulating tumor cells in vitro

The invention discloses a method for capturing, identifying and culturing circulating tumor cells of sarcoma in vitro. The method comprises a step of filtering a peripheral blood sample of a sarcoma patient by using a flexible microfiltration membrane, and cells obtained by filtration can be directly subjected to multiplication culture on the filtration membrane. Immunomagnetic beads of a monoclonal antibody combination group coupled with the anti-human leukocyte surface antigen CD45 can be used for negative enrichment and then multiplication culture is carried out in a cell culture bottle, and the captured or cultured cells can be subjected to subtype identification, characterization and counting by adopting an iFISH technology. It is found for the first time that the flexible microfiltration membrane can be used for capturing and culturing the sarcoma circulating tumor cells, and the flexible microfiltration membrane has no toxic effect on the sarcoma circulating tumor cells. The invention not only provides an effective means for real-time monitoring of relapse and metastasis processes of sarcoma patients and chemotherapy drug resistance monitoring, but also can perform drug sensitivity experimental verification on CTC after multiplication culture, and provides a powerful weapon for accurate diagnosis and treatment of sarcoma.
Owner:PEOPLES HOSPITAL PEKING UNIV

Use of plac8 as a target in preparation of tumor treatment drugs

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Application of brucein D and Vinetoram in preparation of medicine for treating acute myelogenous leukemia

The invention discloses an application of brucein D and Vinetoram in preparation of a medicine for treating acute or drug-resistant myelogenous leukemia. Through a large number of experimental screening, the brucein D and the Venotocork are combined for medication, and the test result shows that the brucein D and the Venotocork act on different targets and different signal channels of AML cells to generate a remarkable synergistic anti-tumor effect, and after the brucein D and the Venotocork are combined, the proliferation inhibition and apoptosis induction effects on the AML cells can be directly enhanced, and the anti-tumor effect of the Venotocork D and the AML cells can be improved. The compound can also reverse the drug resistance possibly occurring when the Vinetoram is singly used, and also has a remarkable killing effect on chemotherapy drug-resistant AML cells at the same time. The composition provided by the invention can reduce the dosage of antitumor drugs, reduce drug resistance, reduce adverse reactions and improve the life quality of patients, and has important application prospects.
Owner:NANJING UNIV OF TRADITIONAL CHINESE MEDICINE

3, 4, 5-trihydroxy phenylacetate compound as well as preparation method and application thereof

The invention relates to a 3, 4, 5-trihydroxy phenylacetate compound and a preparation method and application thereof, the 3, 4, 5-trihydroxy phenylacetate compound belongs to a compound shown in a general formula I and a general formula II, R1, R2 and corresponding derivatives thereof can activate a copper death pathway mediated by endogenous copper ions, have an obvious anti-tumor effect, and have a stronger anti-tumor effect in chemotherapy of drug-resistant tumors. The tumors comprise melanoma, liver cancer, gastric cancer, breast cancer, oral squamous cell carcinoma and the like. The compound is a non-copper ion carrier compound with a brand new structure, induced copper death does not depend on exogenous copper ions, and endogenous copper ions are dissociated by reducing the content of glutathione which is a copper ion chelate in cells. The copper ions are further combined with microfilament skeleton related protein to cause disintegration of the microfilament skeleton, so that copper death is induced. The compound disclosed by the invention can be used as a potential lead compound for inducing endogenous copper ion mediated copper death for anti-tumor therapy.
Owner:XIAMEN UNIV

Compositions and methods for enhancing cancer chemotherapy

To provide safe and effective compositions and methods for enhancing the efficacy and / or reducing the side effects of cancer chemotherapy and increasing the sensitivity of chemotherapy-resistant cancer cells.SOLUTION: Nutritional supplements comprising fish oil and selenium have been found to provide various activities that are beneficial in treating cancer and related conditions. The supplement provides a synergistic effect in reducing cancer cell growth when used in combination with a chemotherapeutic agent and can reduce growth in drug resistant cancer cells when used in combination with a chemotherapeutic agent to which the cells are resistant. Effects in reducing angiogenesis, reducing metastasis, decreasing the number of circulating cancer cells, and altering AXL signaling have also been found. The use of the supplement was found to reduce the wasting associated with cachexia and decrease circulating cytokines associated with inflammation. The overall effect was found to prolong survival in a clinical study.SELECTED DRAWING: Figure 1
Owner:シャーホウンサイモン

Composition of selected tumor-infiltrating lymphocytes and related methods for their production and use.

Various embodiments of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched with tumor-reactive cells. The embodiments also provide methods for producing tumor-reactive TILs enriched with tumor-reactive cells, and the use of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. According to the embodiments, a tumor-reactive T cell enriched pharmaceutical T lymphocyte infiltration (TIL) composition comprises an oligoclonal population of tumor-infiltrating T cells, including tumor-derived CD4+ and CD8+ T cells, with up to 40 clones constituting 40% of the TCR frequency in the population. Embodiments of the present invention are particularly useful for treating tumors that are resistant or refractory to conventional chemotherapy, or that have become resistant or refractory.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Small molecule polypeptide and application thereof in preparation of medicine for treating chemotherapy drug-resistant non-small cell lung cancer

The invention relates to the technical field of medicine, in particular to application of small molecule polypeptide in preparation of a medicine for treating chemotherapy-resistant non-small cell lung cancer. Pharmacological experiment results show that the targeted SLC3A2 ubiquitinated small molecule polypeptide provided by the invention can obviously inhibit occurrence and development of lung adenocarcinoma and partially reverse drug resistance of lung adenocarcinoma cells to cis-platinum, and can be used for treating lung adenocarcinoma and chemotherapy drug resistance of lung adenocarcinoma. The invention provides a new drug source for treatment of lung adenocarcinoma and drug resistance of lung adenocarcinoma chemotherapy.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

Chemotherapy drug resistance marker RAD51AP1 for ovarian cancer drug resistance diagnosis or prognosis evaluation in ovarian cancer treatment with platinum drugs and application of chemotherapy drug resistance marker RAD51AP1

The invention discloses a chemotherapy drug resistance marker RAD51AP1 for ovarian cancer drug resistance diagnosis or prognosis evaluation in ovarian cancer treatment with platinum drugs and application of the chemotherapy drug resistance marker RAD51AP1, and relates to the technical field of biological medicines. A series of experiments prove that the high expression of RAD51AP1 is the key for causing the platinum drug chemotherapy resistance of an ovarian cancer patient, the expression level of the RAD51AP1 in an ovarian cancer platinum chemotherapy resistance sample is remarkably increased, and the RAD51AP1 is expected to become a chemotherapy resistance marker for diagnosis or prognosis evaluation of the drug resistance of the ovarian cancer treated by the platinum drug clinically; rAD51AP1 knock-down can lead to cancer cell apoptosis and enhance the curative effect of cis-platinum, and shows the potential of the cis-platinum as a chemotherapy drug resistance marker and a new target for targeted therapy; the combination of RAD51AP1 knockout and cisplatin treatment can significantly inhibit tumor growth, which prompts that RAD51AP1 may be used as an important target in cisplatin treatment, and a new tumor treatment strategy is expected to be developed for the target.
Owner:BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV

RNA compounds for treating proliferative disorders

PCT designated stage expiredWO2025125372A1Peptide/protein ingredientsTransferasesDiseaseOncology
The invention is based on in vitro transcribed or in vitro synthesized RNA compounds for a translation of tumor suppressor proteins in subjects suffering from a proliferative disease such as cancer. The invention provides the RNA compounds, as well as compositions for their delivery or administration to subjects. The invention in some embodiments provides novel avenues for treating chemotherapy resistant cancer diseases.
Owner:JOHANN WOLFGANG GOETHE UNIV FRANKFURT AM MAIN

Application of honokiol in the preparation of a drug for treating retinoblastoma

This application relates to the technical field of drug applications. This application discloses the use of honokiol in the preparation of a drug for treating retinoblastoma. It is discovered for the first time that honokiol has a new effect in treating retinoblastoma, can effectively inhibit the proliferation of retinoblastoma cells, and is of great significance for the development of new drugs for treating retinoblastoma. Experiments have proven that honokiol can inhibit the proliferation of RB cells by promoting apoptosis of RB cells and inducing cell cycle arrest. This application also discovers for the first time that honokiol has a significant therapeutic effect on multi-drug resistant RB cells, providing a new idea for solving the clinical problem of RB chemotherapy resistance. Experiments have proven that honokiol still maintains good sensitivity to RB drug-resistant cells, and its killing effect on RB / CBP drug-resistant cells is similar to that of RB non-drug-resistant cells.
Owner:BEIJING TONGREN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

EGFR-MEK-TZ three-combined molecule LN-1 and preparation method and application thereof

The invention discloses an EGFR (Epidermal Growth Factor Receptor)-MEK (Methyl Ester Kinase)-TZ three-combination molecule LN-1 as The structure of the EGFR-MEK-TZ three-joint molecule LN-1 is as shown in the specification. The invention provides an EGFR-MEK-TZ three-combination molecule LN-1 with an anti-tumor effect, the EGFR-MEK-TZ three-combination molecule LN-1 can inhibit proliferation of prostate cancer Lancap and PC3 cells, can induce apoptosis of the prostate cancer Lancap and PC3 cells, and can play the anti-tumor effect through multiple mechanisms, and three-combination targeted therapy can provide a new treatment strategy for CPRC chemotherapy drug resistance.
Owner:THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1

Circular RNA (Ribonucleic Acid) as well as mutant and related application thereof

The invention discloses a circular RNA (Ribonucleic Acid) as well as a mutant and related application thereof, and relates to the field of medicines. The invention discloses the new application of hsacirc0069982 for the first time, hsacirc0069982 can be used as an aptamer RNA (Ribonucleic Acid) medicine for resisting hnRNP family proteins, and tumor metastasis can be remarkably inhibited and chemotherapy resistance of tumors can be reversed by increasing the expression quantity of hsacirc0069982; it is found that hsacirc0069982 can directly interact with hnRNP M, depending on a hsacirc0069982 key area, by optimizing and modifying the sequence of the area, an enhanced mutant can be obtained, the sequence is shown as SEQ ID NO: 2-6, and the enhanced mutant shows the hnRNP M binding capacity higher than that of a wild type. Through verification, the hsacirc0069982 and the enhanced mutant thereof can effectively inhibit tumor metastasis and chemotherapy drug resistance, and a new way and means are provided for tumor treatment.
Owner:SICHUAN UNIV